# GenScript

largest B2B producer of plasmids and lentiviral libraries; screening on primary T-cells.

Source: https://en.bioecon.ru/companies/genscript/
Updated: 2026-06-24

- Country: China

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Headcount | 6,165 employees (2025-12-31) | https://www.genscript.com/gsfiles/IPO/Annual_Report_2025.pdf?1327877738=, https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0413/2026041300567.pdf |
| Revenue | US$959.5 million (group) (2025-12-31) | https://www.genscript.com/gsfiles/IPO/Annual_Report_2025.pdf?1327877738=, https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0413/2026041300567.pdf |
| Revenue | US$388.7 million (ProBio segment) (2025-12-31) | https://www.prnewswire.com/news-releases/genscript-biotech-corp-reports-strong-fy2025-results-as-integrated-platform-strategy-and-global-execution-drive-high-quality-growth-302714527.html |
| Production site | Nanjing and Zhenjiang, China; Hopewell, New Jersey, USA (2023-01-01) | https://www.genscript.com/gsfiles/IPO/GenScript_Biotech_Corporation_2025_Investor_Day_CEO_Remarks_EN.pdf?v=4, https://www.prnewswire.com/news-releases/chinas-largest-commercial-gmp-plasmid-manufacturing-facility-is-put-into-operation-genscript-probio-expanding-manufacturing-capacity-again-301439016.html, https://www.probiocdmo.com/gsfiles/techfiles/Making%20Cell%20and%20Gene%20Therapy%20Manufacturing%20Accessible.pdf |
| Capacity | 16,000L GMP manufacturing capacity; dedicated commercial GMP plasmid facility (6,400m²) in Zhenjiang; cGMP sgRNA/DNA payload facility expansions | https://www.genscript.com/genscript-doubles-cgmp-sgrna-and-non-viral-dna-payload-manufacturing-capacity.html, https://www.genscript.com/gsfiles/IPO/GenScript_Biotech_Corporation_2025_Investor_Day_CEO_Remarks_EN.pdf?v=4, https://www.prnewswire.com/news-releases/chinas-largest-commercial-gmp-plasmid-manufacturing-facility-is-put-into-operation-genscript-probio-expanding-manufacturing-capacity-again-301439016.html, https://www.probiocdmo.com/gsfiles/techfiles/Making%20Cell%20and%20Gene%20Therapy%20Manufacturing%20Accessible.pdf |
| Certification | GMP compliant (FDA, EMA, NMPA, PMDA, MFDS) | https://www.genscript.com/genscript-doubles-cgmp-sgrna-and-non-viral-dna-payload-manufacturing-capacity.html, https://www.genscript.com/gsfiles/IPO/GenScript_Biotech_Corporation_2025_Investor_Day_CEO_Remarks_EN.pdf?v=4, https://www.probiocdmo.com/gsfiles/techfiles/Making%20Cell%20and%20Gene%20Therapy%20Manufacturing%20Accessible.pdf |
| Regulatory approval | 140+ IND clearances globally as of 2025; 60+ ongoing CMC projects | https://www.genscript.com/genscript-doubles-cgmp-sgrna-and-non-viral-dna-payload-manufacturing-capacity.html, https://www.genscript.com/gsfiles/IPO/GenScript_Biotech_Corporation_2025_Investor_Day_CEO_Remarks_EN.pdf?v=4, https://www.prnewswire.com/news-releases/genscript-biotech-corp-reports-strong-fy2025-results-as-integrated-platform-strategy-and-global-execution-drive-high-quality-growth-302714527.html, https://www.probiocdmo.com/gsfiles/techfiles/Making%20Cell%20and%20Gene%20Therapy%20Manufacturing%20Accessible.pdf |
| Funding | Group cash/bank balances: US$843.1 million as of 2025-12-31 [medium confidence] | https://www.genscript.com/gsfiles/IPO/Annual_Report_2025.pdf?1327877738=, https://www.genscript.com/gsfiles/IPO/GenScript_Biotech_Corporation_2025_Investor_Day_CEO_Remarks_EN.pdf?v=4, https://www.probiocdmo.com/gsfiles/techfiles/Making%20Cell%20and%20Gene%20Therapy%20Manufacturing%20Accessible.pdf |

Independent sources: prnewswire.com, probiocdmo.com, www1.hkexnews.hk

## Technologies

- [CRISPR screening as a service](https://en.bioecon.ru/technology/crispr-screening-as-a-service/)
- [DNA synthesis & gene foundry](https://en.bioecon.ru/technology/dna-synthesis-gene-foundry/)
- [iGEM infrastructure, BioBricks and standard genetic parts](https://en.bioecon.ru/technology/igem-infrastructure-biobricks-standard-genetic-parts/)
- [Strain engineering (synbio CRO)](https://en.bioecon.ru/technology/strain-engineering-synbio-cro/)